iSpecimen Inc. (NASDAQ:ISPC) Short Interest Down 33.1% in March

iSpecimen Inc. (NASDAQ:ISPC) was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 79,700 shares, a decrease of 33.1% from the February 28th total of 119,100 shares. Based on an average daily volume of 841,800 shares, the days-to-cover ratio is presently 0.1 days. Approximately 9.7% of the shares of the stock are short sold.

iSpecimen Trading Down 2.5 %

ISPC traded down $0.03 on Friday, hitting $1.15. 28,437 shares of the company’s stock were exchanged, compared to its average volume of 411,960. iSpecimen has a fifty-two week low of $1.09 and a fifty-two week high of $11.80. The stock has a market cap of $1.11 million, a price-to-earnings ratio of -0.06 and a beta of 1.65. The firm has a 50-day moving average price of $1.74 and a 200-day moving average price of $3.14.

Hedge Funds Weigh In On iSpecimen

A hedge fund recently bought a new stake in iSpecimen stock. Bridgeway Capital Management LLC purchased a new position in shares of iSpecimen Inc. (NASDAQ:ISPC) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 21,800 shares of the company’s stock, valued at approximately $58,000. Bridgeway Capital Management LLC owned 2.27% of iSpecimen as of its most recent SEC filing. 13.62% of the stock is owned by hedge funds and other institutional investors.

iSpecimen Company Profile

iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers.